Evidence map›Paper›PMID 30104243›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2018

SAMHD1 Posttranscriptionally Controls the Expression of Foxp3 and Helios in Human T Regulatory Cells.

Yong Chan Kim, Kee Kwang Kim, Jeongheon Yoon, David W Scott, Ethan M Shevach

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Coexpression of Helios in Foxp3Disease markers · 2021
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Yong Chan KimDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814.ORCID 0000-0003-4447-1042
Kee Kwang KimDepartment of Biochemistry, Chungnam National University, 34134 Daejeon, South Korea; and.
Jeongheon YoonDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814.
David W ScottDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814; david.scott@usuhs.edu eshevach@niaid.nih.gov.
Ethan M ShevachLaboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814 david.scott@usuhs.edu eshevach@niaid.nih.gov.ORCID 0000-0003-1607-4664
Uniformed Services University of the Health Sciences · USChungnam National University · KRNational Institutes of Health · US

Funding

Studies of Human T Regulatory CellsZIAAI001046 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SHEVACH, ETHAN · 2009 to 2025
$10.5M
Induction of Tolerance to FVIII in HemophiliaR01HL126727 · NHLBI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI PRATT, KATHLEEN PALMER, SCOTT, DAVID WILLIAM · 2015 to 2022
$3.2M
Studies of Human T Regulatory CellsZ01AI001046 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SHEVACH, ETHAN · 2008 to 2008
$639k
Engineered CARs Targeting FVIII-specific T and B CellsR21HL127495 · NHLBI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI SCOTT, DAVID WILLIAM · 2016 to 2017
$424k
Intramural NIH HHS Z01 AI001046NHLBI NIH HHS R01 HL126727NHLBI NIH HHS R21 HL127495
6 · The paper itself

Abstract

Clinical application of Ag-specific T regulatory cells (Tregs) offers promise for the treatment of undesirable immune diseases. To achieve this goal, long-term expansion of Tregs is required to obtain sufficient numbers of cells. However, human Tregs are not stable ex vivo. Therefore, we previously developed an innovative Treg expansion protocol using 25mer-phosphorothioated random oligonucleotides (ODNps25). The addition of ODNps25 successfully resulted in the stabilization of engineered Ag-specific Tregs; however, the mechanism is not fully characterized. We first identified sterile α motif histidine-aspartate-domain containing protein 1 (SAMHD1) as an ODNps25-binding protein using a UV-cross-linking pull-down strategy. SAMHD1 physically interacted with the 3' untranslated region of Foxp3 mRNA and was translocated from nucleus to cytoplasm after ODNps25 treatment. Importantly, addition of ODNps25 enhanced the interaction of SAMHD1 and Foxp3 mRNA significantly, and this interaction was increased by TCR stimulation. Because ODNps25 binds to the nuclease (HD) domain of SAMHD1, we then established that overexpression of a dNTPase-deficient mutant (D137N) in Tregs significantly stabilized the expression level of the Foxp3 protein. Furthermore, we found that TCR stimulation upregulates phosphorylation of the threonine residue (Thr592), which is a regulatory site to control SAMHD1 activity, and phosphorylation of Thr592 is critical to control SAMHD1 activity to stabilize the expression of Foxp3 and Helios in Tregs. Taken together, we suggest that the interaction of ODNPs25 in HD or phosphorylation of Thr592 by TCR stimulation interferes with nuclease activity of SAMHD1, thereby stabilizing 3' untranslated region of Foxp3 and Helios mRNAs in long-term culture.

Indexed as

3' Untranslated RegionsAdultAgedCell Culture TechniquesCells, CulturedFemaleForkhead Transcription FactorsGene Expression RegulationHumansIkaros Transcription FactorMaleMiddle AgedOligodeoxyribonucleotidesSAM Domain and HD Domain-Containing Protein 1T-Lymphocytes, Regulatory3' Untranslated RegionsCPG-oligonucleotideForkhead Transcription FactorsFOXP3 protein, humanIkaros Transcription FactorIKZF2 protein, humanOligodeoxyribonucleotidesSAM Domain and HD Domain-Containing Protein 1SAMHD1 protein, human

Identifiers

PMID30104243
PMCPMC6125212
OpenAlexW2887744838

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.